Update on stem cell transplantation for systemic sclerosis: recent trial results

Area of Science:

• Immunology
• Rheumatology
• Hematology

Background:

• Systemic sclerosis (SSc) is a complex autoimmune disease causing fibrosis and organ damage.
• Progressive diffuse cutaneous SSc with organ involvement has a poor prognosis.
• Autologous hematopoietic stem cell transplantation (HSCT) is explored as an intensive immunosuppressive therapy.

Purpose of the Study:

• To evaluate the efficacy and safety of HSCT in treating systemic sclerosis.
• To assess the long-term survival benefit and risks associated with HSCT for SSc.

Main Methods:

• Review of pilot studies, registry analyses, and Phase II (ASSIST) and Phase III (ASTIS) clinical trials.
• Analysis of patient outcomes including skin thickening, functional ability, organ function, and survival rates.

Main Results:

• HSCT has demonstrated rapid and sustained improvements in skin and functional capacity.
• Stabilization of major organ function and some improvement in vital capacity were observed.
• Phase III ASTIS trial results support long-term survival benefits of HSCT.

Conclusions:

• HSCT shows promise for improving outcomes in systemic sclerosis.
• Further research is needed to balance HSCT benefits against risks like treatment-related mortality and long-term complications.
• Optimizing patient selection and transplant protocols may enhance HSCT efficacy for SSc.